Combination pills for ALK-positive lung cancer after lorlatinib stops working
Part of Cancer clinical trials.
This trial tests a combination of two targeted therapy pills (ensartinib and anlotinib) in patients whose ALK-positive lung cancer has stopped responding to lorlatinib. The goal is to see if this new combination can help shrink or control the cancer when standard treatment has failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced (stage IIIB or IV) non-small cell lung cancer that is ALK-positive (a specific gene change).
- You must be 18 years or older.
- Your cancer must have stopped responding to lorlatinib, a pill used to treat ALK-positive lung cancer.
- For the first part: you cannot have taken ensartinib before, and you can have had at most two other ALK-targeting pills and up to two courses of chemotherapy.
- You must be able to have an MRI with contrast if you have signs of cancer spread to the brain or spinal fluid (for certain cases).
- You should not have another active cancer, and you must not have had major surgery in the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study combines a daily targeted pill (lorlatinib) with a short course of radiation or surgery to treat ALK-positive lung cancer. The goal is to see if this two-step approach delays the cancer from growing.
This trial tests lorlatinib, a pill that targets a specific genetic change in lung cancer cells (ALK-positive). It may help people with advanced lung cancer who have not yet had treatment for their advanced disease.
This trial tests combining chemotherapy with lorlatinib for people with ALK-positive lung cancer that has spread outside the brain while on lorlatinib. The goal is to see if adding chemo can help control the cancer when it starts growing again.
This trial compares a newer targeted pill (lorlatinib) with standard chemoradiation (chemo plus radiation) for people with stage III ALK-positive lung adenocarcinoma. The goal is to see if lorlatinib alone works better than standard treatment and causes fewer side effects.
This study is testing a targeted therapy called lorlatinib in people with advanced ALK-positive lung cancer. It aims to see how well this oral medication works in a real-world setting.
This trial tests a targeted pill, lorlatinib, for people with advanced ALK-positive non-small cell lung cancer (NSCLC) who have not received previous treatment for advanced disease. It aims to see how well the drug works in this setting.
Hear when a new ALK-positive, Locally Advanced or Metastatic (TNM Stage IIIB-IV) Non-small Cell Lung Cancer That Has Developed Resistance to Prior Treatment With Lorlatinib trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.